Assessing the importance of domestic vaccine manufacturing centers: An overview of immunization programs, vaccine manufacture, and distribution
Artículo

Publication date
2018Metadata
Show full item record
Cómo citar
Rey Jurado, Emma
Cómo citar
Assessing the importance of domestic vaccine manufacturing centers: An overview of immunization programs, vaccine manufacture, and distribution
Author
Abstract
Vaccines have significantly reduced the detrimental effects of numerous human infectious diseases worldwide, helped to reduce drastically child mortality rates and even achieved eradication of major pathogens, such as smallpox. These achievements have been possible due to a dedicated effort for vaccine research and development, as well as an effective transfer of these vaccines to public health care systems globally. Either public or private institutions have committed to developing and manufacturing vaccines for local or international population supply. However, current vaccine manufacturers worldwide might not be able to guarantee sufficient vaccine supplies for all nations when epidemics or pandemics events could take place. Currently, different countries produce their own vaccine supplies under Good Manufacturing Practices, which include the USA, Canada, China, India, some nations in Europe and South America, such as Germany, the Netherlands, Italy, France, Argentina, and Brazil, respectively. Here, we discuss some of the vaccine programs and manufacturing capacities, comparing the current models of vaccine management between industrialized and developing countries. Because local vaccine production undoubtedly provides significant benefits for the respective population, the manufacture capacity of these prophylactic products should be included in every country as a matter of national safety.
Patrocinador
Millenium Institute on Immunology and Immunotherapy from Chile
P09/016-F
CONICYT/FONDECYT POSTDOCTORADO
3160249
FONDECYT
1150862
1070352
1050979
1040349
1100926
1110397
1131012
1140010
1150173
1161525
1160695
1140011
3140455
1160336
1170964
FONDEF
D11I1080
Max Planck Society
Indexation
Artículo de publicación ISI
Quote Item
Frontiers in Immunology Volumen: 9 Número de artículo: 26
Collections
The following license files are associated with this item:
Except where otherwise noted, this item's license is described as Attribution-NonCommercial-NoDerivs 3.0 Chile
Related items
Showing items related by title, author, creator and subject.
-
Suárez, Eugenio; Smit, Jennifer S.; Bosch, F. Xavier; Nieminen, Pekka; Chen, Chien-Jen; Torvinen, Saku; Demarteau, Nadia; Standaert, Baudouin (ELSEVIER SCI LTD, 2008-09-15)Mathematical models provide valuable insights into the public health and economic impact of cervical cancer vaccination programmes. An in-depth economic analysis should explore the effects of different vaccine-related ...
-
Avendano, Alfredo; Avendano, Alfredo; Lagos, Rosanna; Horwitz, Isidoro; Cayazzo, Marisol; Fritzell, Bernard; Meschievitz, Carlton; Levine, Myron (1993)The safety and immunogenicity of a vaccine against Haemophilus influenzae type b consisting of purified polyribosylribitol phosphate conjugated to tetanus toxoid (PRP-T) were evaluated in 277 Chilean infants who were ...
-
O'Ryan Gallardo, Miguel; Bandyopadhyay, Ananda S.; Villena Martínez, Rodolfo; Espinoza Barrios, Mónica; Novoa, José; Weldon, William C.; Oberste, Steven; Self, Steve; Borate, Bhavesh R.; Asturias, Edwin J.; Clemens, Ralf; Orenstein, Walter; Jimeno, José; Ruettimann, Ricardo; Costa Clemens, Sue Ann (Elsevier, 2015)Background Bivalent oral poliovirus vaccine (bOPV; types 1 and 3) is expected to replace trivalent OPV (tOPV) globally by April, 2016, preceded by the introduction of at least one dose of inactivated poliovirus vaccine ...